Almirall S.A. stock (ES0157097017): dermatology-focused pharma after Q1 2025 update

Spanish dermatology specialist Almirall S.A. reported its Q1 2025 results and confirmed its full-year guidance, while its shares continue to trade below past highs. What drives the business – and what matters for international and US-focused investors?

Spanish dermatology group Almirall S.A. remains in focus after publishing its results for the first quarter of 2025 and reiterating its full-year 2025 guidance for revenue and core EBITDA. The company highlighted solid performance in its core dermatology portfolio, particularly in Europe, according to a results release dated April 29, 2025, on its investor relations site and related coverage by Spanish business media on the same date, both of which pointed to continued momentum in key products.

As of: 22.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Almirall
• Sector/industry: Pharmaceuticals, dermatology
• Headquarters/country: Spain
• Core markets: Europe and selected international markets
• Key revenue drivers: Prescription dermatology medicines and related therapies
• Home exchange/listing venue: Bolsa de Madrid (ticker ALM)
• Trading currency: EUR

Almirall S.A.: core business model

Almirall S.A. is a mid-sized pharmaceutical company with a primary focus on medical dermatology, meaning prescription treatments for chronic skin diseases such as psoriasis, atopic dermatitis and actinic keratosis. The company historically operated a broader pharma portfolio, but over the last decade it has steadily repositioned itself as a pure-play dermatology specialist in Europe. This strategic pivot is reflected in its recent reports, which emphasize the share of revenues coming from dermatology products.

The company’s business model combines in-house research and development with licensing and collaboration deals. Almirall invests in proprietary molecules, formulations and indications in dermatology, but it also in-licenses compounds or co-develops assets with partners to expand its pipeline and product range. This mix is typical for mid-cap pharma players that aim to balance innovation risk with a more diversified portfolio of assets. Management has repeatedly presented this strategy during recent capital markets and earnings presentations, underscoring dermatology as the key growth engine.

Geographically, Almirall generates a large portion of its revenues in European markets such as Spain, Germany and other EU countries, while also seeking growth opportunities in international markets through partnerships and selective direct presence. The dermatology focus gives the company exposure to underlying secular trends, including an aging population and rising diagnosis and treatment rates for chronic skin conditions. These trends are often cited by industry observers and appear in sector reports from healthcare-focused research providers, though individual projections can vary.

The firm also runs a portfolio of legacy and non-core products, including some primary care and other therapeutic areas. However, recent corporate communications have made clear that strategic priority and resource allocation are heavily tilted toward dermatology, both in terms of marketing push and R&D spending. This allows Almirall to concentrate its commercial infrastructure on dermatologists and relevant hospital channels rather than attempting to compete as a fully diversified large-cap pharma group.

Main revenue and product drivers for Almirall S.A.

Almirall’s revenue base is anchored in a set of key dermatology brands that target chronic and often difficult-to-treat conditions. In Europe, the company’s portfolio includes topical and systemic therapies for psoriasis, acne, rosacea and actinic keratosis, among others. Q1 2025 commentary from the company pointed to ongoing growth in its core dermatology franchises, which helped offset headwinds in other parts of the portfolio, according to the April 29, 2025 earnings materials released on its corporate site.

One structural driver of Almirall’s revenue is the chronic nature of many targeted skin diseases. Patients with psoriasis or atopic dermatitis often require long-term treatment and may cycle through different therapies over time, depending on disease control and tolerability. For drug makers like Almirall, this can support a relatively stable demand profile once products are established in treatment guidelines and reimbursed by payers. However, it also exposes the company to competitive dynamics from generics, biosimilars and newer branded therapies developed by larger global pharma and biotech players.

Almirall’s product strategy includes both prescription topical products and systemic treatments, and in some indications it positions its offerings either as monotherapy options or as part of combination regimens. The company’s R&D pipeline, as presented in recent investor materials and conference presentations in late 2024 and 2025, highlights further pipeline assets for inflammatory skin diseases. These assets are at different stages of clinical development, with timelines and success probabilities that are inherently uncertain, as is typical in pharmaceutical R&D.

Beyond branded dermatology drugs, Almirall also derives revenue from some non-dermatology products and mature brands. Over time, management has considered portfolio optimization measures, such as potential divestments or deprioritization of non-core lines, in order to sharpen the dermatology focus and free up resources for launches and clinical programs. Such portfolio moves are relatively common in the mid-cap pharma space and can impact reported revenues and margins in the near term, while aiming to improve strategic coherence.

Why Almirall S.A. matters for US-focused investors

Although Almirall is listed in Madrid and reports in euros, its activities and partnerships can be relevant for US-focused investors following the global healthcare and dermatology space. The company competes and collaborates with multinational pharma and biotech players that are widely held in US portfolios, and developments in Almirall’s pipeline or marketed products can serve as a read-across for certain dermatology segments. In some cases, Almirall may hold regional rights to assets that global partners commercialize in North America, linking its performance indirectly to US market dynamics.

From a portfolio-construction perspective, Almirall can appear in international or global healthcare funds accessible to US investors, especially those that allocate to European mid-cap pharma. For investors analyzing the dermatology ecosystem more broadly, the company offers an example of a pure-play regional specialist, in contrast to diversified US-based giants that include dermatology among many other therapeutic areas. Earnings trends, regulatory milestones and competitive shifts around Almirall can therefore add nuance to a sector view that might otherwise be dominated by US-listed large caps.

Currency exposure is another factor. Because Almirall reports in euros and generates much of its revenue in Europe, returns for US-based investors are influenced by EUR/USD exchange rate movements in addition to company-specific fundamentals and share-price changes. This currency layer can either amplify or dampen the underlying performance of the stock when viewed in US dollars, similar to other European holdings in a US-centered portfolio.

Conclusion

Almirall S.A. is positioned as a focused dermatology player with a significant presence in European prescription markets and an evolving pipeline aimed at chronic inflammatory skin diseases. Its Q1 2025 results and reaffirmed guidance underline management’s confidence in the current portfolio, while also highlighting the usual execution and R&D risks seen in mid-cap pharma. For internationally oriented and US-based investors following the global healthcare sector, the stock offers insight into how a regional dermatology specialist navigates competition, regulation and currency factors without representing a recommendation to buy or sell. As always, individual portfolio decisions depend on personal risk tolerance, investment horizon and the broader context of diversified holdings.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.